Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Lozano R, Domeque N, Apesteguia AF. Clinical Pharmacology: Advances and Applications. 2013;5(1):153–159. On page 155, "Deriving Michaelis–Menten’s equation,26 View original paper by Lozano R, Domeque N, Apesteguia AF
Saved in:
Main Authors: | Lozano R, Domeque N, Apesteguia AF |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/5b06dddba05b4e019fa00366bcc1ae84 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
by: Lozano R, et al.
Published: (2013) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
by: Frost C, et al.
Published: (2018) -
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
by: Cui Y, et al.
Published: (2014) -
Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
by: Persson PB
Published: (2015) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
by: Frost C, et al.
Published: (2014)